p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy

Myrthala Moreno‐Smith(Gynecologic Oncology Group), Eveline Barbieri(Children's Cancer Center), Silke Paust(Scripps Research Institute), Kevin Aviles-Padilla(Baylor College of Medicine), Jason M. Shohet(University of Massachusetts Chan Medical School), Rana Nikzad(Scripps Research Institute), Anna Lakoma(Baylor College of Medicine), Vivien Sheehan(Emory University), Linda Schild(Amsterdam UMC Location University of Amsterdam), Zaowen Chen(Children's Cancer Center), Ling Tao(Baylor College of Medicine), Jan J. Molenaar(Princess Máxima Center), Kathleen A. Scorsone(Children's Cancer Center), Sanjeev A. Vasudevan(Baylor College of Medicine), Eugene S. Kim(Cedars-Sinai Medical Center), Yankai Zhang(Parker University), Rikhia Chakraborty(Cleveland State University)
Clinical Cancer Research
August 18, 2017
Cited by 25


Related Papers